Apixaban and Limiting Aspirin for Patients With Atrial Fibrillation, Percutaneous Coronary Intervention, and Multimorbidity
Our findings support the standard use of apixaban plus a P2Y<sub>12</sub> inhibitor in patients with AF and ACS/PCI, irrespective of the presence of multimorbidity.
Authors
- Konstantin A. Krychtiuk (ORCID: https://orcid.org/0000-0001-7792-2837)
- Christopher Bull Granger (ORCID: https://orcid.org/0000-0002-0045-3291)
- Roxana Mehran (ORCID: https://orcid.org/0000-0002-5546-262X)
- Ronald Aronson
- Shaun G. Goodman (ORCID: https://orcid.org/0000-0001-8068-2440)
- Stephan Windecker (ORCID: https://orcid.org/0000-0003-2653-6762)
- Karen P. Alexander (ORCID: https://orcid.org/0000-0003-4418-1424)
- Renato D. Lópes (ORCID: https://orcid.org/0000-0003-2999-4961)
- John Hunter Alexander (ORCID: https://orcid.org/0000-0002-1444-2462)
- DANIEL M. WOJDYLA (ORCID: https://orcid.org/0009-0009-3431-2014)
Institutions
- University of Bern (CH)
- University of Alberta (CA)
- Cardiovascular Institute of the South (US)
- University Hospital of Bern (CH)
- Clinical Research Institute (US)
- Bristol-Myers Squibb (United States) (US)
- Mount Sinai Hospital (US)
- Canadian VIGOUR Centre (CA)
- Duke Institute for Health Innovation (US)
- Duke University Health System (US)
- St Michael's Hospital (GB)
Publication Details
- Journal
- JACC Advances
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1016/j.jacadv.2024.101335
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer